Tada, 

The 3 patient limit was part of the 3+3 design during the dose escalation phase. For the Zen-3694 single agent trial, they have already determined the maximally tolerated dose for daily dosing. Last we heard from a couple months ago, they were going to try intermittent dosing (ie two weeks on, one week off) that has been used with other pan BET inhibitors. So they are close to, if not already started, to entering the patient expansion stage that will expand to a larger patient pool at the optimized dose. 

BearDownAZ